Tags

Type your tag names separated by a space and hit enter

Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma.
Curr Med Res Opin. 2006 Mar; 22(3):463-70.CM

Abstract

OBJECTIVE

To determine resource utilization in controller naïve children diagnosed with asthma receiving initial therapy with fluticasone propionate (FP) and salmeterol (SAL) in a single inhaler (FSC), FP alone, montelukast (MON), inhaled corticosteroid (ICS) + SAL from separate inhalers, or ICS + MON.

RESEARCH DESIGN AND METHODS

A retrospective, observational, 18-month (6-month pre-index and 12-month follow-up) database study using medical and pharmacy claims from a 5 million member managed care organization. Multivariate modeling was used to evaluate post-index resource utilization and asthma-related costs. Refill rates during the 12-month follow-up period were compared across cohorts.

RESULTS

The study included controller-naïve children (n = 9192) aged 4-17 years with an asthma diagnosis. Children treated with FSC were significantly less likely to receive additional prescriptions for short-acting beta-agonists compared with all other cohorts (p <or= 0.007) and oral corticosteroids compared with the MON, ICS + SAL, and ICS + MON cohorts (p <or= 0.009). Children receiving FSC were also significantly less likely to add another controller therapy compared with children started on FP alone, MON, or ICS + SAL (p <or= 0.001) and to receive care in an emergency department or hospital compared with children receiving ICS + MON (p < 0.001). The number of prescriptions for FSC in the 12-month post-index period was greater (p < 0.05) than the number of ICS claims in the FP, ICS + SAL, and ICS + MON cohorts. Compared with FSC, the adjusted total asthma-related post-index costs were greater (p <or= 0.008) in the MON and ICS + MON cohorts. Although adherence was greater with MON compared with FSC, MON was associated with less favorable clinical outcomes and greater resource utilization and costs.

CONCLUSION

FSC in children is associated with improved clinical outcomes and decreased resource utilization compared with other controller regimens.

Authors+Show Affiliations

Infomed NW and University of Washington, Seattle, WA, USA. econmed@msn.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16574030

Citation

Stempel, David A., et al. "Resource Utilization With Fluticasone Propionate and Salmeterol in a Single Inhaler Compared With Other Controller Therapies in Children With Asthma." Current Medical Research and Opinion, vol. 22, no. 3, 2006, pp. 463-70.
Stempel DA, Riedel AA, Carranza Rosenzweig JR. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. Curr Med Res Opin. 2006;22(3):463-70.
Stempel, D. A., Riedel, A. A., & Carranza Rosenzweig, J. R. (2006). Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. Current Medical Research and Opinion, 22(3), 463-70.
Stempel DA, Riedel AA, Carranza Rosenzweig JR. Resource Utilization With Fluticasone Propionate and Salmeterol in a Single Inhaler Compared With Other Controller Therapies in Children With Asthma. Curr Med Res Opin. 2006;22(3):463-70. PubMed PMID: 16574030.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. AU - Stempel,David A, AU - Riedel,Aylin Altan, AU - Carranza Rosenzweig,Jacqueline R, PY - 2006/4/1/pubmed PY - 2006/8/11/medline PY - 2006/4/1/entrez SP - 463 EP - 70 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 22 IS - 3 N2 - OBJECTIVE: To determine resource utilization in controller naïve children diagnosed with asthma receiving initial therapy with fluticasone propionate (FP) and salmeterol (SAL) in a single inhaler (FSC), FP alone, montelukast (MON), inhaled corticosteroid (ICS) + SAL from separate inhalers, or ICS + MON. RESEARCH DESIGN AND METHODS: A retrospective, observational, 18-month (6-month pre-index and 12-month follow-up) database study using medical and pharmacy claims from a 5 million member managed care organization. Multivariate modeling was used to evaluate post-index resource utilization and asthma-related costs. Refill rates during the 12-month follow-up period were compared across cohorts. RESULTS: The study included controller-naïve children (n = 9192) aged 4-17 years with an asthma diagnosis. Children treated with FSC were significantly less likely to receive additional prescriptions for short-acting beta-agonists compared with all other cohorts (p <or= 0.007) and oral corticosteroids compared with the MON, ICS + SAL, and ICS + MON cohorts (p <or= 0.009). Children receiving FSC were also significantly less likely to add another controller therapy compared with children started on FP alone, MON, or ICS + SAL (p <or= 0.001) and to receive care in an emergency department or hospital compared with children receiving ICS + MON (p < 0.001). The number of prescriptions for FSC in the 12-month post-index period was greater (p < 0.05) than the number of ICS claims in the FP, ICS + SAL, and ICS + MON cohorts. Compared with FSC, the adjusted total asthma-related post-index costs were greater (p <or= 0.008) in the MON and ICS + MON cohorts. Although adherence was greater with MON compared with FSC, MON was associated with less favorable clinical outcomes and greater resource utilization and costs. CONCLUSION: FSC in children is associated with improved clinical outcomes and decreased resource utilization compared with other controller regimens. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/16574030/Resource_utilization_with_fluticasone_propionate_and_salmeterol_in_a_single_inhaler_compared_with_other_controller_therapies_in_children_with_asthma_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079906X89711 DB - PRIME DP - Unbound Medicine ER -